Latest Audeara (ASX:AUA) News

Pentanet led the technology board with a 53.33% weekly rise, while Ava Risk Group and Acusensus also posted strong gains. Software subscriptions, AI tools and cloud services drove many company updates, but some early share-price gains faded.

Audeara has reached a key milestone as its chip-level AI licensing partnership with Optek enters commercial production, receiving initial purchase orders worth about A$31,000. This validates Audeara’s scalable fee-per-chip licensing model and sets the stage for broader applications in audio and hearing health.

Audeara Ltd posted record FY26 cash receipts of $4.2 million and unaudited revenue of $4.44 million, driven by progress in AI audio licensing, exclusive assistive listening deals, and a large-scale Auracast deployment across retirement villages.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Audeara has locked in exclusive Australian rights to a customised assistive listening device from ShokzHear, aiming to tackle widespread listening challenges among schoolchildren through government-backed programs.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

Tech microcaps swung hard as funding news, contract wins and disclosure issues collided. The biggest falls came where investors saw either forced selling or more cash needs ahead.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

One microcap exploded higher on a tiny capital raise, while several software names were sold hard despite reporting growth. The week split cleanly between “cash in the bank” stories and “still burning cash” worries.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.